// App-Quantinova.ai

1058 : PBRM1 defects are synthetic lethal with PARP and ATR inhibitors

Researchers

Presenter

  • Roman Merial Chabanon

Principal Investigators

  • Lo Colmet-Daage

  • Thomas Eychenne

  • Nicolas Dorvault

  • Ilirjana Bajrami

  • Marlne Garrido

  • Suzanna Hopkins

  • Cornelia Meisenberg

  • Andrew Lamb

  • Theo Roumeliotis

  • Samuel Jouny

  • Clmence Astier

  • Asha Konde

  • Genevive Almouzni

  • Jyoti Choudhary

  • Jean-Charles Soria

  • Jessica Downs

  • Christopher J. Lord

  • Sophie Postel-Vinay

Medical Centers

  • Gustave Roussy, Villejuif, France

  • The Francis Crick Institute, London, United Kingdom

  • Institute for Cancer Research, London, United Kingdom

  • Sage Bionetworks, Seattle, WA

  • Institut Curie, Paris Cedex, France

  • Université Paris Sud, Paris Saclay, Le Kremlin‐Bicêtre, France

  • Gustave Roussy Cancer Campus and U981 INSERM, ATIP-Avenir group, Villejuif, France

Locations

  • France

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Clear cell renal carcinoma

  • Non Small Cell Lung cancer

  • Small cell lung cancer

  • Renal cell carcinoma

  • Advanced biliary tract carcinoma

  • Osteosarcoma

  • Lung Cancer

  • Solid malignancies

Biomarkers

  • Apurinic/Apyrimidinic Endodeoxyribonuclease 1

  • Ataxia Telangiectasia And Rad3-Related Protein

Drug/Treatment

  • Methadone hydrochloride

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved